XML 32 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Indebtedness - Additional Information (Detail)
1 Months Ended 12 Months Ended
Dec. 13, 2019
USD ($)
Tranch
Nov. 14, 2017
USD ($)
shares
$ / shares
Sep. 30, 2018
USD ($)
Dec. 31, 2019
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jul. 31, 2017
USD ($)
Debt Instrument [Line Items]              
Debt instrument, face amount       $ 820,000,000      
Proceeds for issuance of notes allocated to equity           $ 570,000,000  
Amount paid for capped calls transactions           50,901,000  
Prepayment fee percentage       2.00%      
Line of credit facility, lenders fee       1.75%      
Debt extinguishment loss     $ (2,300,000)   $ (2,322,000)    
Long-term debt       $ 681,900,000 420,554,000    
Convertible Debt, The Term Loan, The Revolver and The Mortgage Loans [Member]              
Debt Instrument [Line Items]              
Long-term debt       681,900,000      
Interest expense related to debt facilities       30,700,000 33,700,000 $ 5,800,000  
2024 Convertible Notes [Member]              
Debt Instrument [Line Items]              
Debt instrument, face amount   $ 570,000,000.0   $ 570,000,000 $ 570,000,000    
Debt instrument, maturity date   Nov. 15, 2024          
Debt instrument, interest rate per annum   1.50%          
Debt instrument, payment frequency       The 2024 Notes were issued at face value and bear interest at the rate of 1.50% per annum, payable semi-annually in cash on each May 15 and November 15, commencing on May 15, 2018.      
Debt instrument, conversion rate   0.013621          
Debt instrument, conversion price | $ / shares   $ 73.42   $ 73.42      
Proceeds for issuance of notes allocated to equity   $ 161,100,000          
Offering costs   4,200,000          
Debt issuance costs   $ 10,600,000          
Effective interest rate percentage       6.90% 6.90% 6.90%  
Capped calls strike price | $ / shares   73.42          
Capped calls cap price | $ / shares   104.88          
Amount paid for capped calls transactions   $ 50,900,000          
Debt discount       $ 120,182,000 $ 140,206,000    
Debt issuance costs       7,922,000 $ 9,240,000    
Credit agreement interest rate per annum   1.50%          
2024 Convertible Notes [Member] | Fundamental Change [Member]              
Debt Instrument [Line Items]              
Debt instrument, repurchase price percentage   100.00%          
2024 Convertible Notes [Member] | Minimum [Member] | Beneficial Owner [Member] | Fundamental Change [Member]              
Debt Instrument [Line Items]              
Voting percentage   50.00%          
2024 Convertible Notes [Member] | Common Stock [Member]              
Debt Instrument [Line Items]              
Debt instrument, convertible into shares | shares   7,763,552          
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member]              
Debt Instrument [Line Items]              
Debt instrument, maturity date Dec. 20, 2023            
Debt instrument, interest rate per annum 8.50%            
Current borrowing capacity $ 500,000,000.0            
Number of tranches | Tranch 2            
Prepayment fee percentage 2.00%            
Debt discount       9,400,000      
Debt issuance costs       700,000      
Proceeds after debt discount and issuance cost       $ 244,900,000      
Credit agreement interest rate per annum 8.50%            
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch A [Member]              
Debt Instrument [Line Items]              
Current borrowing capacity $ 250,000,000.0            
Line of credit facility, lenders fee 1.75%            
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | December 2019 Term Loan [Member] | Tranch B [Member]              
Debt Instrument [Line Items]              
Current borrowing capacity $ 250,000,000.0            
Line of credit facility, lenders fee 1.75%            
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | Minimum [Member] | December 2019 Term Loan [Member]              
Debt Instrument [Line Items]              
Prepayment fee percentage 1.00%            
Biopharma Credit PLC and Biopharma Credit Investments V (Master) LP [Member] | Maximum [Member] | December 2019 Term Loan [Member]              
Debt Instrument [Line Items]              
Prepayment fee percentage 2.00%            
MidCap Financial Amended and Restated Credit and Security Agreement [Member]              
Debt Instrument [Line Items]              
Debt instrument, interest rate per annum             6.25%
Current borrowing capacity             $ 60,000,000.0
Credit agreement interest rate per annum             6.25%
MidCap Financial Amended and Restated Credit and Security Agreement [Member] | Revolving Loan [Member]              
Debt Instrument [Line Items]              
Debt instrument, interest rate per annum             3.95%
Current borrowing capacity             $ 40,000,000.0
Credit agreement interest rate per annum             3.95%